Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis.

Pharmacotherapy - 1 Mar 2024

Lonabaugh Kevin, Li Galvin, List Rhonda, Huang Reyna, James Amber, Barros Andrew, Somerville Lindsay, Albon Dana

Abstract excerpt

INTRODUCTION: The introduction of the highly effective modulator therapy elexacaftor-tezacaftor-ivacaftor (ETI) has revolutionized the care of persons with cystic fibrosis (PwCF) with major improvements seen in lung function and body mass index. The effects of ETI therapy in real-world cohorts on other parameters such as cholesterol levels are largely unknown. METHODS: A single-center, retrospective chart review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Indoles

Share to Pyrazoles

Share to Pyridines

Share to Pyrrolidines

Share to Quinolones

Source

Identifiers

PMID: 38143243
DOI: 10.1002/phar.2903

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis.PMID 38143243Read ↗

Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis.Semantic proximity Read ↗

Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis.Semantic proximity Read ↗

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.Semantic proximity Read ↗

Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index.Semantic proximity Read ↗

Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.Semantic proximity Read ↗

The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis.Semantic proximity Read ↗

Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis.Semantic proximity Read ↗

Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis.Semantic proximity Read ↗

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges.Semantic proximity Read ↗

Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal studySemantic proximity Read ↗

Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.